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Objectives: People living with HIV (PLWH) are at increased risk of infections with resistant organisms
due to more frequent healthcare utilization. Our objective was to investigate the association between HIV
and antimicrobial resistance (AMR).
Methods: We searched MEDLINE, EMBASE, Web of Science, LILACS and African Journals Online. Studies
were eligible if they reported on AMR for colonization or infection with bacterial pathogens (excluding
mycobacteria and bacteria causing sexually transmitted infections) and were stratified by HIV status,
species and antimicrobials tested. Pooled odds ratios were used to evaluate the association between HIV
and resistance.
Results: In total, 92 studies published between 1995 and 2020 were identified. The studies included the
following organisms: Staphylococcus aureus (n ¼ 47), Streptococcus pneumoniae (n ¼ 28), Escherichia coli
(n ¼ 6) and other Gram-negative bacteria. PLWH had a 2.12 (95%CI 1.36e3.30) higher odds for coloni-
zation and 1.90 (95%CI 1.45e2.48) higher odds for infection with methicillin-resistant S. aureus, a 2.28
(95%CI 1.75e2.97) higher odds of infection with S. pneumoniae with decreased penicillin susceptibility,
and a 1.59 (95%CI 0.83-3.05) higher odds of resistance to third-generation cephalosporins in E. coli and
Klebsiella pneumoniae.
Conclusion: This review shows an increased risk of AMR in PLWH across a range of bacterial pathogens
and multiple drug classes. The lack of laboratory capacity for identifying AMR, and limited access to
alternative treatment options in countries with the highest burden of HIV, highlight the need for more
research on AMR in PLWH. Overall, the quality of studies was moderate or low, which may impact the
findings of this review. Ioana D. Olaru, Clin Microbiol Infect 2021;▪:1
© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).Introduction
The discovery of antimicrobials has led to a ‘golden age’ in
medicine which has enabled the effective treatment of a large
number of once deadly infections. The emergence and worldwide
dissemination of antimicrobial resistance (AMR) is threatening to
overturn these advances, leading to increased morbidity, mortality
and healthcare costs [1]. AMR is of particular concern in low- andhool of Hygiene and Tropical
7HT, United Kingdom.
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, https://doi.org/10.1016/j.cmmiddle-income settings where treatment options are limited due to
cost and availability of drugs. Among the main drivers for AMR are
inappropriate antimicrobial use, transmission of resistant patho-
gens in healthcare settings, and rapid dissemination of resistant
pathogenic strains due to international travel and trade [2]. On an
individual level, prior antimicrobial use, healthcare contact and
underlying comorbid conditions are recognized risk factors for
infection and colonization with resistant organisms [3].
There are almost 38 million people living with HIV (PLWH)
worldwide, with the highest prevalence of infection in countries in
sub-Saharan Africa [4]. PLWH have more frequent hospital admis-
sions, clinic visits and antimicrobial treatment courses compared toof Clinical Microbiology and Infectious Diseases. This is an open access article under
icrobial resistance and HIV infection: a systematic review and meta-
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the acquisition of and infection with resistant bacteria. Hospital
admissions for acute bacterial infections are more frequent in HIV-
infected than in HIV-uninfected individuals [5,6]. Overall, bacterial
infections (not including tuberculosis) are one of themain causes of
hospitalization and death in PLWH worldwide, with almost a third
of all hospital admissions and a quarter of all deaths due to bacterial
infections [7]. More frequent hospital admissions may lead to an
increased number of antimicrobial prescriptions and a higher risk
of acquisition of resistant pathogens during hospitalization. Addi-
tionally, there is a higher prevalence of chronic conditions such as
kidney and liver diseases, which also require more frequent clinic
appointments and hospital admissions among PLWH [8,9]. In the
United States, prescriptions for multiple antimicrobial drug classes
are more common among elderly HIV-infected individuals than in
their HIV non-infected counterparts [10]. Furthermore, antimicro-
bial prescriptions are more frequent among HIV-infected in-
dividuals even before HIV diagnosis, as shown by a study from
Denmark [11]. With the roll-out of widespread antiretroviral ther-
apy (ART) and improved early diagnosis and treatment of HIV, the
impact of these factors on the prevalence of resistance may have
changed over time.
Antimicrobials such as co-trimoxazole, macrolides and anti-
mycobacterial agents are also recommended as prophylaxis for
PLWH [12,13]. The indication may vary by CD4 cell count, age,
geographical setting and prior medical history. Use of co-
trimoxazole prophylaxis in high-income settings is decreasing
due to early diagnosis of HIV and ART use. However, in low-income
settings co-trimoxazole prophylaxis is recommended by the WHO
for all childrenwith HIV, and for adults with advanced HIV infection
or who are living in areas wheremalaria and bacterial infections are
prevalent, irrespective of ART [12]. Thus, co-trimoxazole prophy-
laxis, which has significantly reduced mortality [14], is currently
widely used throughout sub-Saharan Africa.
Although HIV infection is not known to have a direct effect on
the colonization and infection of an individual with resistant or-
ganisms, PLWH have a multitude of indirect risk factors. There are
limited data on the association between HIV infection and bacterial
AMR, and to our knowledge this has never been reviewed
systematically.
The aim of this systematic review is to determine whether HIV
infection is associated with colonization or infection with
antimicrobial-resistant bacteria.
Methods
The review is focused on bacterial pathogens causing infection
or colonizing individuals with HIV infection. Mycobacteria and or-
ganisms causing sexually transmitted infections were excluded
because this association has recently been reviewed [15] and
because of the differences in transmission pathways for sexually
transmitted infections.
Eligible publications were identified using the search strategy
described in the Supplementary Material Table S2. The search
strategy was applied to MEDLINE, EMBASE, Web of Science and
LILACS databases up to week 3 of 2020. The African Journals Online
and PubMed databases were searched for additional publications.
The search was updated to June 2020. References of included
studies and other reviews were manually searched for relevant
publications. Articles identified were imported into the biblio-
graphic software manager Endnote X7 (Clarivate Analytics, Phila-
delphia, PA, USA). Titles and abstracts were screened for eligibility
by IDO and KK in duplicate.
Studies were included if they reported resistance data for
colonization or infection by HIV status and stratified the results byPlease cite this article as: Olaru ID et al., The association between antim
analysis, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmbacterial species and antimicrobials tested. Colonization and
infection were considered as defined by the authors of the
respective studies. Studies describing species from the same fam-
ilydsuch as Escherichia coli and Klebsiella pneumoniae (Enter-
obacteriaceae)dwhich did not present data by bacterial species
were grouped in the analysis. No restriction with regards to
geographical region, language or year of publication was applied.
Case series were excluded. The review followed the PRISMA
guidelines. The study protocol was registered with PROSPERO
(CRD42020178907). The search strategy and analyses are described
in the Supplementary Material.
Analyses were conducted using STATA (version 15, Stata-Corp,
TX, USA). A descriptive analysis was performed for all eligible
studies. If at least five studies reporting on the same organism (or
group) and resistance to the same antimicrobial class were iden-
tified, then a random effects meta-analysis using the DerSimonian
and Laird method was performed in STATA (using ‘metan’). The
meta-analyses were also stratified according carriage/colonization
or infection. The pooled odds ratio estimates were grouped by or-
ganism, infection versus colonization and drug tested. Sensitivity
analyses were performed to determine whether findings were
consistent across different groups (Supplementary Material). Meta-
analyses for proportions were performed using the package ‘met-
aprop’. Heterogeneity of studies was evaluated using Cochrane
recommendations [16] using the I2 statistic. Heterogeneity was
considered substantial if I2 >50%.
Completeness of reporting was assessed using the STROBE
checklist [17], and for each item studies were graded into three
categories: ‘no information provided or unclear description’, ‘some
information but insufficient’, ‘clear information provided’. The
modified NewcastleeOttawa scale was used to evaluate the quality
of the studies [18].
Results
Characteristics of identified studies
Of 21 489 unique citations identified by the search, 299 were
selected for full-text review, of which 71 were suitable for inclusion
in the main analysis. An additional 21 publications were identified
from reference review. A total of 92 citations were included in the
qualitative analysis (Fig. 1). Most studies were from either the
United States (n ¼ 32, 35%) or South Africa (n ¼ 21, 23%). Fig. 2
shows where the studies were conducted. About half of the
studies were conducted in low- and middle-income countries
(n ¼ 50, 54%).
Most studies described resistance in a single pathogen (n ¼ 83,
90%) while nine studies presented data for multiple organisms.
AMR in Streptococcus pneumoniae was described in 28 studies
(carriage n ¼ 1, infection n ¼ 27), Staphylococcus aureus in 47
(carriage n ¼ 29; infection n ¼ 18) and other organisms in 22
(carriage n ¼ 6; infection n ¼ 16). Studies in Enterobacteriaceae
were on E. coli (n ¼ 6), Salmonella spp. (n ¼ 7), K. pneumoniae
(n ¼ 3), and Shigella spp. (n ¼ 3). Supplementary Material Table S3
presents an overview of the studies included.
Patient characteristics
Studies included 40 625 PLWH and 17 187 704 individuals
without HIV. Most studies were conducted in inpatients (n ¼ 44,
48%), or a combination of inpatients and outpatients (n ¼ 10, 11%);
18 studies (20%) reported on outpatients only, and six (7%) on other
settings such as prisons (n ¼ 3), youth centres (n ¼ 1), shelters
(n ¼ 1) and individuals recruited from the community (n ¼ 1)
(Supplementary Material Table S3). One study reported on isolatesicrobial resistance and HIV infection: a systematic review and meta-
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Fig. 1. PRISMA diagram for a systematic review of the risk of antimicrobial resistance in bacterial infections in adults with HIV infection. Other reasons for exclusion were: reported
data from neonates or HIV-exposed and uninfected children (n ¼ 9); presented data from studies with <20 participants (n ¼ 9); studies were comparing different populations and/
or settings (n ¼ 3); no stratification by organism (n ¼ 3); reported on inappropriate samples (n ¼ 2); did not account for repeated sampling of the same individual (n ¼ 2);
publication based on data already included in the review (n ¼ 2); excluded participants with HIV (n ¼ 1).
Fig. 2. Map of countries with studies included in a systematic review of the risk of antimicrobial resistance in bacterial infections in adults with HIV infection. Countries are shaded
if at least one study on antibacterial resistance among HIV-positive and HIV-negative people was identified in this review. The size of the dot represents the number of studies from
the respective country.
I.D. Olaru et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3collected as part of laboratory surveillance and did not specify the
source of the isolates; 13 studies did not provide details on the
healthcare setting. Most of the studies were conducted in a single
facility (n ¼ 54, 59%).
Most studies reported data from adults (n ¼ 53, 58%), while 15
(16%) included only children and 22 (24%) included both adults and
children. For two studies, participant age was not reported.
HIV status was determined by performing an HIV test as part of
the study procedures (n¼ 26 studies) or was obtained from patientPlease cite this article as: Olaru ID et al., The association between antim
analysis, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmrecords or as part of the medical history (n ¼ 52 studies). In 14
studies, HIV status ascertainment was not clearly described.
Few studies reported on ART coverage (n ¼ 17, 18%) and co-
trimoxazole prophylaxis (n ¼ 22, 24%) among HIV-infected pa-
tients. CD4 cell counts at the time of the study were reported for 39
studies (42%). Mean/median CD4 cell counts were <200 cells/mL in
12 studies (31%) and 200 in 25 studies (64%). For two studies the
severity of the immunosuppression could not be determined.
Forty-five (49%) of the studies collected data prospectively, whileicrobial resistance and HIV infection: a systematic review and meta-
i.2021.03.026
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bases; one study used both prospective and retrospective data
collection, and three (3%) did not specify how data collection was
performed.
The pooled prevalence of resistance to selected antimicrobials
by HIV status is shown in Table 1 and in Supplementary Material
Figs S2 and S3.Antimicrobial resistance in Staphylococcus aureus
Of the 47 studies describing AMR prevalence in S. aureus, 29
studies (62%) focused on colonization only (nasal: n ¼ 23; multiple
sites n ¼ 6), and 18 (38%) on infections (bacteraemia: n ¼ 5; skin
and soft tissue infections: n ¼ 5; respiratory infections: n ¼ 2;
multiple sites: n ¼ 6). Among studies evaluating methicillin-
resistant S. aureus (MRSA) colonization, six studies used methods
enabling direct MRSA identification: chromogenic media (n ¼ 5)
and molecular methods (n ¼ 1). Most studies reported predomi-
nantly on patients with community-acquired infections (n ¼ 10,
56%), while four (22%) included patients with hospital-acquired
infections and four (22%) did not describe the type of infection.
The studies included a total of 27 364 PLWH and 17 159 190 in-
dividuals without HIV infection. Half of the studies (24/47) and 89%
of PLWH were from United States. Most studies (41/47, 87%) were
conducted after the introduction of widespread ART. The propor-
tion of individuals on co-trimoxazole prophylaxis was not consis-
tently reported (n ¼ 11, 23%) and ranged from 0 to 89%.
PLWH had 2.12 (95%CI 1.36e3.30) higher odds for colonization
and 1.90 (95%CI 1.45e2.48) higher odds for infection with MRSA
compared with HIV-negative individuals. Eleven studies evaluated
co-trimoxazole susceptibility of S. aureus isolates. The pooled OR for
co-trimoxazole resistance was 1.40 (95%CI 0.49e3.99) for coloni-
zation and 2.89 (95%CI 0.48e17.37) for infection, comparing PLWH
with HIV-negative individuals. Heterogeneity in ORs was high
across studies (I2 range 82e98%, Fig. 3c,d). Among individuals with
S. aureus colonization, the odds of MRSA carriage were higher
among PLWH than in those without HIV infection (Supplementary
Material Fig. S4).Antimicrobial resistance in Streptococcus pneumoniae
A total of 28 studies evaluated AMR in S. pneumoniae, including
9239 PLWH and 8368 individuals without HIV infection; South
Africa contributed the majority of the HIV-positive patients (83%).
Studies were mostly conducted before the widespread availability
of ART (n ¼ 18, 64%). Reporting of ART (1/28) and co-trimoxazole
prophylaxis (8/28) usage was very rare. Where described, the
proportion of PLWH reported to take co-trimoxazole prophylaxis
ranged between 0 and 67%. More than two thirds of the studies
described invasive pneumococcal disease (n ¼ 20, 71%), whileTable 1
Antimicrobial resistance to selected drugs
Organism Antimicrobial Number o
resistance
Staphylococcus aureus (infection) MRSA 14
S. aureus (colonization) MRSA 29
Co-trimoxazole 5




Data were not pooled if there were three or fewer studies reporting prevalence by organ
heterogeneous. Studies where prevalence could not be calculated for both HIV-infected an
Please cite this article as: Olaru ID et al., The association between antim
analysis, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmisolates were cultured frommultiple sample types in seven studies
(30%). One study reported on pneumococcal carriage.
Nine studies reported on co-trimoxazole resistance. S. pneu-
moniae isolates from PLWH had a 2.28 (95%CI 1.75e2.97) higher
odds of having decreased penicillin susceptibility compared to
isolates from individuals without HIV. The pooled OR for co-
trimoxazole resistance was 2.29 (95%CI 1.31e4.00). Heterogeneity
of studies was moderate to substantial (I2 60% and 75%, respec-
tively, Fig. 3a,b).
Antimicrobial resistance in Escherichia coli and Klebsiella
pneumoniae
Four studies described resistance in E. coli, two in K. pneumoniae,
and one in both E. coli and K. pneumoniae isolates from patients
presenting with infections. These studies included 849 HIV-
infected and 12 573 non-HIV-infected individuals. Isolates were
from blood (n ¼ 3), stool (n ¼ 2), urine (n ¼ 1) and respiratory
samples (n ¼ 1). The OR for the presence of resistance to third-
generation cephalosporins and co-trimoxazole in E. coli and
K. pneumoniae causing infections was 1.59 (95%CI 0.83e3.05) and
2.43 (95%CI 1.36e4.32) respectively (Fig. 3e,f). Heterogeneity was
high across studies for both third-generation cephalosporin resis-
tance (I2 94%) and co-trimoxazole resistance (I2 78%).
Quality of reporting in studies included
Completeness of reporting according to the STROBE checklist
was moderate in the majority of studies (66/92, 72%) (Fig. 4).
Sources of bias, sample size and generalizability of results were
often not discussed. Also, most studies did not report on the
number of participants or samples excluded from the analysis or
the reasons for exclusion. When using the modified
NewcastleeOttawa Scale, most studies were of moderate (n ¼ 30)
or low (n ¼ 57) quality. Only seven studies were of high quality.
Discussion
This review synthesizes for the first time data on AMR in PLWH
compared to that in HIV-negative individuals. It shows that, for
several important pathogens, PLWH are more likely to be infected
or colonized with resistant bacterial strains than people without
HIV infection. This holds true for two major Gram-positive and
some Gram-negative organisms and for multiple antimicrobial
classes. The higher prevalence of resistance among PLWH is of
particular concern in low-income settings where alternative
treatment options are limited by their availability and cost [19]. Co-
trimoxazole may increase the risk of colonization with resistant
Gram-negative and Gram-positive organisms [20e22]. Therefore,
resistance is not surprising given the wide use of co-trimoxazole asf studies reporting
by HIV status
Pooled prevalence of resistance (95%CI)
HIVþ HIVe
49% (32e65) 35% (25e44)
9% (7e11) 6% (4e8)
65% (44e86) 55% (46e64)
29% (23e36) 15% (11e19)
38% (30e47) 20% (13e28)
14% (8e20) 19% (12e26)
8% (4e12) 8% (5e12)
ism and drug class, or if the number of studies was small and estimates were highly
d non-infected individuals were also excluded. MRSA,methicillin-resistant S. aureus.
icrobial resistance and HIV infection: a systematic review and meta-
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Fig. 3. Pooled odds ratios for antimicrobial resistance in bacteria isolated from HIV-infected individuals compared with those without HIV. Streptococcus pneumoniae penicillin non-
susceptibility (a) and co-trimoxazole resistance (b); Staphylococcus aureus methicillin resistance (c) and co-trimoxazole resistance (d); Escherichia coli and Klebsiella pneumoniae
third-generation cephalosporin resistance (e) and co-trimoxazole resistance (f).
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Fig. 4. Quality of reporting for studies according to the STROBE criteria. The horizontal bars represent the proportion of studies providing complete (green), some/insufficient
(yellow) or no/unclear (red) information on the respective items.
I.D. Olaru et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6prophylaxis in PLWH in general; however, only a fraction of the
studies presented data on co-trimoxazole use among their partic-
ipants. The degree of immunosuppression and ART influence the
risk of infection and hospitalization [23], but less than 20% of the
studies reported the proportion of PLWH on ART, and only 41%
described CD4 cell counts among PLWH.
Many penicillins and cephalosporins are readily available,
inexpensive drugs used to treat infections caused by a wide variety
of organisms. For S. aureus, the methicillin resistance gene (mecA) is
especially problematic as it confers resistance not just to fluclox-
acillin but to almost all b-lactam drugs, including third-generation
cephalosporins. Treatment of systemic MRSA infections is hence
particularly challenging in low- and middle-income settings, as
vancomycin and linezolid are not widely available and are expen-
sive and difficult to use safely in PLWH.
This systematic review found that HIV infection is associated
with methicillin resistance in S. aureus in studies predominantly
from the United States and conducted prior to 2010. The steady
decrease in MRSA infections in the United States since 2005 is
attributed to the rigorous introductionof enhanced infection control
programmes [24]. This declinewas also observed in PLWH, although
MRSA incidence remained higher than in the general population
[25]. Peoplewho inject drugs andmenwhohave sexwithmen are at
increased risk for MRSA [26,27]. Given that these populations are
more likely to be HIV-infected than the general population in the
United States [28,29], the higher prevalence of MRSAmay be due to
confoundingby these factors.However, the associationbetweenHIV
infection and MRSA was also found in studies from sub-Saharan
Africa [30] where heterosexual transmission of HIV is predomi-
nant, and therefore the association cannot be fully explained by this
confounder. Previous studies have found that low CD4 cell counts
and unsuppressed HIV viral load, injected drug use and identifying
as a man who has sex with men are all associated with MRSA in
PLWH [31,32]. The high prevalence of MRSA colonization in PLWH
may be attributed to hospital admissions caused by HIV-related
immunosuppression [33]. On the other hand, the association be-
tween HIV infection and resistance may be confounded by the
presence of high-risk sexual activities [34]. Most studies in this re-
view reported on community-acquired MRSA infections reflecting
the widespread dissemination of successful MRSA clones.
This review found that the higher odds for MRSA colonization
and infection among people with HIV was consistent across
different levels of immunosuppression, ART use and countryPlease cite this article as: Olaru ID et al., The association between antim
analysis, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmincome, although some comparisons may be limited by the very
small number of studies in the respective subgroups.
Co-trimoxazole resistance in S. aureus occurs either by muta-
tions in the dihydrofolate reductase gene or by acquisition of
variant dihydrofolate reductase genes by horizontal gene transfer
[35]. While in Europe the prevalence of co-trimoxazole resistance
in S. aureus is relatively low [36], this is not the case for sub-Saharan
Africa and Asia [37,38]. The higher prevalence of resistance in these
settings may be explained by the widespread use of co-trimoxazole
and other sulphonamide-based drugs for treatment and prevention
of infections [37,39], and potentially by the expansion of particular
clonal types within the HIV population [30]. This is also reflected by
the findings of this review which suggest an association between
HIV and co-trimoxazole resistance, although estimates varied
widely across studies.
S. pneumoniae is a major cause of pneumonia and meningitis;
individuals with immunodeficiencies are at increased risk for
invasive disease [40]. b-Lactam drugs, namely benzylpenicillin or
amoxicillin, are the mainstay treatment for pneumococcal disease.
Recent antimicrobial use, young age, previous hospitalization,
infectionwith certain capsular serotypes, and geographical location
are all risk factors for resistant S. pneumoniae strains causing
invasive disease [41]. The epidemiology of S. pneumoniae non-
susceptible to penicillin varies geographically, and in the late
1990s the majority of invasive pneumococcal disease cases in the
United States were attributed to pneumococcal conjugate vaccine
(PCV7) serotypes [42].
Prevalenceof co-trimoxazole resistancealsovaries geographically
and is influencedbypriorexposureeither to co-trimoxazole [22] or to
other sulphonamides suchas sulfadoxineepyrimethaminewhichare
used in Africa for malaria treatment and preventive therapy in
pregnancy [43].
Our review shows that HIV infection is associatedwith penicillin
non-susceptibility and co-trimoxazole resistance in S. pneumoniae,
with one in three isolates cultured from PLWH showing non-
susceptibility to penicillin and co-trimoxazole, although this may
be overestimated by preferential sampling of people with HIV
infection. Given that all studies presenting co-trimoxazole resis-
tance data were conducted in sub-Saharan Africa, it is highly likely
that a considerable proportion of PLWH had received co-
trimoxazole prophylaxis. Most studies on S. pneumoniae were
published before the ART roll-out, and therefore these results may
not reflect the current situation.icrobial resistance and HIV infection: a systematic review and meta-
i.2021.03.026
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Enterobacteriaceae, but they suggest a higher odds of resistance to
third-generation cephalosporins and co-trimoxazole in peoplewith
HIV infection, although the confidence interval crossed one for the
former. Comparisons of AMR prevalence for other drug classes were
precluded by the small number of studies identified. Given that
third-generation cephalosporin resistance is associated with
resistance to other drug classes, severe infections may require
treatment with broad-spectrum antibiotics such as carbapenems.
In contrast to high-income settings, where carbapenems usually
are available but their use is restricted, these agents are usually
unavailable in low-income settings or their use is cost-prohibitive.
Overall this systematic reviewshows an associationbetweenHIV
infection and bacterial AMR across multiple pathogens and anti-
microbial classes, although for co-trimoxazole, resistance may not
be of clinical significance for some infections. Because of the di-
versity in study settings and populations, and the small number of
studies identified, we were unable to assess the trend in AMR
prevalence over time. Only 14 studies reported data collected after
2010 and five after 2015, thus precluding conclusions on the current
epidemiology of AMR in these settings. Results were consistent
across time periods, suggesting that the association between HIV
infection and AMR is still relevant despite the relatively small
number of more recent studies. This highlights the need for studies
and surveillance to report on resistance prevalence according toHIV
status, especially in studies from settings with a high HIV burden.
Despite the comprehensive search strategy, without restriction
by language, year of publication and geography, only a small
number of countries are represented in this review. For example,
there were very few studies from South America and Asia. For in-
dividual pathogens, the majority of studies are from a single
country; most of the studies of S. aureus were from the USA, and
most of the studies of S. pneumoniae were from South Africa.
Consequently, the results of this review may not be generalizable
beyond these countries. Despite the high burden of HIV in sub-
Saharan Africa, there are few data on HIV and AMR for most
countries apart from South Africa. Additionally, there was sub-
stantial heterogeneity among studies which is not surprising given
the differences in settings, patient populations, sample types and
laboratory methods used for testing. Further heterogeneity may
have been introduced by preferential sampling of people with HIV
leading to more frequent diagnosis of infection as compared to
individuals uninfected with HIV. The high heterogeneity between
studies may impact on the generalizability of these findings. For
most pathogens, a meta-analysis could not be performed because
of the small number of studies. Because this review included
observational studies, findings may have been affected by
confounding.
This is, to our knowledge, the first systematic review evaluating
the association between HIV infection and AMR in a wide range of
bacterial pathogens. A comprehensive assessment of the quality of
reporting was performed using the STROBE checklist.
The findings of this review underscore the need for further
studies evaluating the association between HIV and AMR, espe-
cially from countries with a high HIV burden [7]. Most studies
included were published before 2010 and were of moderate and
low quality, whichmay affect the validity of our findings. This study
further highlights the need for a better understanding of AMR
prevalence in low-income settings and on the extent to which
people with HIV may be at increased risk for infections with
resistant bacterial pathogens, emphasizing the need for improved
antimicrobial resistance testing and reporting. Increasing diag-
nostic capacity and AMR surveillance, as well as promoting further
research into AMR and HIV, could ultimately lead to improved
management of HIV-infected patients.Please cite this article as: Olaru ID et al., The association between antim
analysis, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmTransparency declaration
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